Founded in 1769, Semmelweis University is the oldest medical school in Hungary. The faculty became an independent medical school after the Second World War and developed into a university teaching medicine, dentistry, pharmacy, health science, and health management, as well as physical education and sport science. The university is named after Ignác Semmelweis , the obstetrician who discovered the cause of puerperal fever in the 1840s.The university has around 10,000 students from 60 nations over five continents. Its five faculties offer courses from undergraduate to doctorate level in Hungarian, English, and German. Foreign students account for about 18% of the total community.Semmelweis University is the largest health care institution in Hungary, with over 9,000 employees covering about 6% of the health care needs of the country’s population.With a quarter of a million of books, Semmelweis University has one of the biggest and best-furnished medical-biological collections in Hungary, and among the Hungarian universities, Semmelweis produces the greatest number of publications. The university is deeply involved in the patient care of the Great-Budapest region. Of its 3000 clinical beds, 75% take part in the regional medical care and some special outpatients' departments also supply the teaching hospitals with patients needed for the training.The portrait of Maria Theresa in the Assembly Hall of the University still commemorates the founding of the Medical Faculty by the Empress of Austria-Hungary more than 230 years ago, forging a continuous link in the education and training of medical students.The name of the University honors Ignác Semmelweis, a former professor of the Medical Faculty between 1855 and 1865, who discovered the cause and prevention of puerperal fever. Semmelweis was the first Hungarian university, which started to offer international courses at the Faculty of Medicine in German in 1983. The English programs started four years later, in 1987. Nowadays, the university enrolls more than 200 new international students each year. Still, students from Germany form the majority of the international student body, although numbers from Israel, Scandinavia, Ireland and Cyprus show consistent growth in recent years.The General Medicine program is listed by the WHO and it is recognized without any licensing examinations in all European Union countries The program leading to the Doctor of Medicine degree consists of six years: two years of general medical studies, three years of clinical studies, and one year of a rotating internship. International students enrolled in the English program are mostly from the EU, Norway, Israel, Cyprus, Iran, Japan, and the USA.The Semmelweis University seeks motivated candidates for the program with a solid background in biology and chemistry. In addition to these subjects, students must pass an entrance exam in English. The application deadline is in April and the course starts in September. Entrance exams are arranged at several locations in Europe, Israel, North America, Asia, and Africa.Since 1 September 2014, the Faculty of Physical Education and Sport science has been separated from Semmelweis University and continues to operate as an independent institution under the name University of Physical Education. Wikipedia.
News Article | May 18, 2017
NANOBIOTIX ANNOUNCES FIRST POSITIVE HUMAN DATA SHOWING THAT NBTXR3 COULD BECOME A BACKBONE IN IMMUNO-ONCOLOGY Paris, France and Cambridge, Massachusetts, (USA) May 18, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. Laurent Levy, CEO of Nanobiotix said, "Being able to transform cold tumors into hot tumors is one of the most challenging and promising topics in oncology. This preliminary clinical data indicates that NBTXR3 could play a key role in unlocking this potential. Given NBTXR3's universal type mode of action and good safety profile, NBTXR3 could change the treatment landscape in numerous solid tumor cancers." Many tumors exhibit little or no response to therapies targeting the immune system and are considered "cold". The explanation for the lack of response in its simplest form is a lack of immunogenicity. The ability of NBTXR3 to generate intratumoral immunogenic cell death (ICD) could be a key to significantly increase the number of patients who can engage their immune system to fight their cancer. To undertake this research, Nanobiotix used the available patient samples from its more advanced indication of soft tissue sarcoma -- a typical "cold" tumor. These findings demontrated that NBTXR3 plus radiotherapy induces a specific adaptive immune pattern, which could potentially contribute to converting a "cold" tumor into a "hot" tumor. In this study, radiotherapy alone did not show any impact on triggering adaptive immune response. Specific adaptive immune pattern induced by NBTXR3 when exposed to radiation therapy in Soft Tissue Sarcoma (STS) patients (#e14615) Jérôme Galon, Marick Laé, Zsuzsanna Papai, Philippe Rochaix, Laszlo Csaba Mangel, Bernhard Mlecnik, Fabienne Hermitte, Zoltan Sapi, Martine Delannes, Tamas Tornoczky, Anne Vincent-Salomon, Sylvie Bonvalot; INSERM, Paris, France; Institut Curie, Paris, France; Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; Pecs University, Pecs, Hungary; HalioDX, Marseille, France; Semmelweis University, Budapest, Hungary. In this study, tumors from the ongoing two-arm Phase II/III clinical trial were examined both pre- and post-treatment in patients with locally advanced soft tissue sarcoma who had received either NBTXR3 with radiotherapy (14 patients) or radiotherapy alone (12 patients). The results observed in the post-treatment examination of patients who received both NBTXR3 and radiotherapy, showed a significant increase of immune cell infiltration (CD3+, CD8+). In contrast, there were no differences observed between pre- and post-treatment examination where patients received radiotherapy alone. Similarly, patients who received NBTXR3 plus radiotherapy were found to have an increased immunoscore post-treatment, compared to those who received radiotherapy alone. The upregulation of pan-immune gene expression and specifically, the expression of adaptive immunity genes between pre- and post-treatment, was pronounced in the post-treatment results of patients who received NBTXR3 plus radiotherapy compared to those who received radiotherapy alone. Furthermore, a functional analysis of upregulated genes in NBTXR3 plus radiotherapy showed a specific enrichment of cytokine activity (IL7, IFNA, IL16, IL11, IFNG), adaptive immunity (RAG1, GZMA, TAP1, TAP2, TBX21, STAT4, IFNG, LCK, LTK, CD37, CD22) and T-cell receptor signaling pathway (CD28, CTLA4, CD274, BTLA, TIGIT, CD40LG, CD5, CD3E, ZAP70). The initial data suggests NBTXR3's potential as an IO agent that could, on its own, trigger a specific immune response against the tumor. A number of upregulated genes correspond to existing or promising IO targets, enabling potential combination of NBTXR3 with therapeutic approaches, like products targeting PD1, PDL1, CTLA4, etc. This data requires confirmation in additional studies. Many IO combination strategies focus on 'priming' the tumor, which is now becoming a prerequisite of turning a "cold" tumor into a "hot" tumor. Compared to other modalities that could be used for priming the tumor, NBTXR3 could have a number of advantages: the physical and universal mode of action that could be used widely across oncology, the one-time local injection and good fit within existing medical practice already used as a basis for cancer treatment, as well as a very good chronic safety profile and well-established manufacturing process. The new clinical data and previous pre-clinical data indicate that NBTXR3 could play a key role in oncology and could become a backbone in immuno-oncology. About NBTXR3 Nanobiotix's lead product, NBTXR3, is a first-in-class radio-enhancer nanoparticle designed for direct injection into cancerous tumors. It has been engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues. NBTXR3 is currently in late-stage clinical development as a single agent. Worldwide clinical development of NBTXR3 now includes trials across 7 patient populations: Phase I/II trial in France and Spain; NBTXR3 + Radiotherapy alone Phase I/II trial by PharmaEngine in Asia-Pacific; NBTXR3 + Radiotherapy & Chemotherapy Phase I/II trial in the U.S First market approval has been filed in the EU. * Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States. Disclaimer This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
News Article | April 13, 2017
Washington, DC, April 13, 2017 (GLOBE NEWSWIRE) -- WASHINGTON, April 13 – The Association of Academic Health Centers (AAHC), in conjunction with its international subsidiary AAHCI, is pleased to announce the next phase of its groundbreaking Aligned Institutional Mission (AIM) Program, a means for academic health centers around the world to optimize and measure the alignment of their education, research, and patient care missions. “AAHC/AAHCI successfully completed the Development Phase of this innovative program and is ready to move forward with the pivotal Pilot Phase that will test and refine program elements to prepare AIM for a full global launch,” said Steven A. Wartman, MD, PhD, AAHC president and CEO. “The feedback we have received from the Development Phase institutions has been outstanding. This pioneering program assists academic health centers on an individualized basis to optimally align their mission components to help create learning health systems for the 21st century.” The Pilot Phase of the program includes seven sites: East Tennessee State (USA), Florida International University (USA), Semmelweis University (Hungary), University of Kansas (USA), University of Malaya (Malaysia), University of Sao Paulo (Brazil), and University of Queensland-Brisbane Diamantina Health Partners (Australia). Following the completion of the Pilot Phase, the association plans a full-scale roll-out to all members in 2018. The AIM program works closely with a distinguished group of consultants, all of whom have had extensive experience in leadership positions with academic health centers: “The AIM Program offers participating institutions a program tool for internal assessment and goal setting; a peer consultant review period; and peer consultant recommendations and strategic improvement planning,” said Wartman. “Participating in the AIM program offered UAMS a valuable opportunity to assess its programs specifically within the framework of how they align our institution with our stated health improvement mission,” said Dan Rahn, MD, chancellor of the University of Arkansas Medical School (an institution that participated in the Development Phase of the program), adding “[u]sing the AIM assessment tool and then hosting a constructive site visit connected all of those changes into a coherent story that illustrates how we moved from our strategic vision to reengineering how we deliver care, manage data, ensure sustainability, align education, research and patient care, and ultimately impact population health.” AAHC is a non-profit association dedicated to advancing health and well-being through the vigorous leadership of academic health centers. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8bb6f932-b76b-43d3-9f00-a8a09bcea085
Wayne State University, Semmelweis University, Office of Technology Transfer and Genesis Theranostix Korlatolt Felelossegu Tarsasag | Date: 2017-06-21
Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.
Agency: European Commission | Branch: H2020 | Program: ERC-STG | Phase: ERC-StG-2015 | Award Amount: 1.02M | Year: 2016
Imagine if tumor growth would be reduced and then kept in a minimal and safe volume in an automated manner and in a personalized way, i.e. cancer drug would be injected using a continuous therapy improving the patients quality of life. By control engineering approaches it is possible to create model-based strategies for health problems. Artificial pancreas is an adequate example for this, where by continuous glucose measurement device and insulin pump it is possible to improve diabetes treatment. Gaining expertise from this problem, the current proposal focuses on taming the cancer by developing an engineering-based medical therapy. The interdisciplinary approach focuses on modern robust control algorithm development in order to stop the angiogenesis process (i.e. vascular system development) of the tumor; hence, to stop tumor growth, maintaining it in a minimal, tamed form. This breakthrough concept could revitalize cancer treatment. It is the right time to do it as some investigations regarding tumor growth modeling have been already done; now, it should be refined by model identification tools and validated on animal trials. The benefit of robust control was already demonstrated in artificial pancreas; hence, it could be adapted to cancer research. The result could end with a personalized healthcare approach for drug-delivery in cancer, improving quality of life, optimizing drug infusion and minimizing treatment costs. This interdisciplinary approach combines control engineering with mathematics, computer science and medical sciences. As a result, the model-based robust control approach envisage refining the currently existing tumor growth modeling aspects, design an optimal control algorithm and extend it by robust control theory to guarantee its general applicability. Based on our research background, validation will be done first in a manually controlled way, but then in an automatic mode to propose it for further human investigations.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-23-2014 | Award Amount: 5.99M | Year: 2015
ADVOCATE brings together top principal investigators from prestigious universities, the public sector, and the private sector to address the most common diseases affecting humanity, as measured by the recent Global Burden of Disease Study. ADVOCATE strives to optimise delivery of oral health and wellbeing to the population in EU Member States. This requires a change in oral health care delivery towards prevention. The change will be achieved by developing a model that promotes a preventive rather than restorative oral health care system: The oral health care model 2020. As the oral health care delivery system is not as overly complex as other health care systems, the oral health care model 2020 may serve as a blueprint for other health care system reforms. The development of this model requires intensive information exchange and engagement of stakeholders to establish a set of key-indicators. These indicators will be used to benchmark health care performance on practice as well as system level. Two types of evidence-based indicators will be selected: Quantitative and qualitative indicators that allow measuring and influencing of either intrinsic motivation or extrinsic motivation incentives towards a patient centred, resilient and prevention oriented oral health care system. ADVOCATE will test this model in a natural environment, and provide evidence-informed policy measures towards its implementation, both for oral health care systems as well as other health care systems. Given the comprehensiveness of the topic, ADVOCATE uses a targeted approach that is entirely focused on the five major root-causes underlying the current suboptimal performance of oral health care systems. Moreover, ADVOCATE has confirmed access to data of eight European oral health care databases; it is well connected to existing initiatives and networks, and has ample support from preventive oriented industry, as exemplified by the financial support provided for the final conference.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.77M | Year: 2015
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population ( 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-2 | Award Amount: 7.70M | Year: 2014
Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test for CAD currently available. CT may become the most effective strategy to reduce the ca. 2 million annual negative ICAs in Europe by enabling early and safe discharge of the majority of patients with an intermediate risk of CAD. To evaluate this, we propose the DISCHARGE project that will be implemented by a multinational European consortium. The core of the project is the DISCHARGE pragmatic randomised controlled trial. The primary hypothesis will be that CT is superior to ICA for major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) after a maximum follow-up of 4 years in a selected broad population of stable chest pain patients with intermediate pretest likelihood of CAD. The trial will include 23 clinical sites from 18 European countries ensuring broad geographical representation. Comparative effectiveness research of complementing work packages include gender-related analysis, systematic review of evidence, cost-effectiveness analysis, and health-related quality of life. DISCHARGE has the capability to influence current standards and guidelines as well as coverage decisions and will raise awareness among patients, health care providers, and decision-makers in Europe about the effectiveness and cost-effectiveness of coronary CT angiography.